Memphasys Limited. (ASX:MEM)


right-arrow Created with Sketch. 0.004 (5.06%)
MCAP $62.58M
Last trade 15.07pm 18/01/2022 20mins delayed

Latest Announcements

20/12/2021 Price SensitivePSMEMMemphasys Limited.
09/12/2021MEMMemphasys Limited.
02/12/2021MEMMemphasys Limited.
26/11/2021MEMMemphasys Limited.
25/11/2021MEMMemphasys Limited.
22/11/2021 Price SensitivePSMEMMemphasys Limited.
03/11/2021 Price SensitivePSMEMMemphasys Limited.
25/10/2021MEMMemphasys Limited.

Company Overview

Memphasys Limited is a bio-separations company developing and commercializing separation techniques based on its membrane technology. It develops medical devices, diagnostics and media with application to assists reproduction technologies in humans and animals. The Company’s lead product is Felix device. The Felix is an automated device for separating quality sperm from a semen sample for the use in human in vitro fertilization (IVF) procedures. The Company's membrane technology utilizes its separation technology along with its multiple devices and hydrogel membranes to fractionate biological molecules. The technology relies on the applied electric field and charged biological molecules. The sample and harvest chamber are formed by placing the separation membrane in between two restriction membranes with restricted pores.

MEM in the news

Reproduction biotechnology and bio-separations company Memphasys (MEM) completes the maiden sale of…
Memphasys (MEM) has enhanced its balance sheet thanks to $3 million in…
Biological separations and reproductive biology company Memphasys (MEM) has entered into a…

Search Previous Announcements